The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Nanotherapeutics to Overcome Conventional Cancer Chemotherapy Limitations
Open accessAbstract
Cancer is one of the major causes of death worldwide and chemotherapy is a major therapeutic approach for the treatment which may be used alone or combined with other forms of therapy. However, conventional chemotherapy suffers lack of aqueous solubility, lack of selectivity and multidrug resistance. Nanotherapeutics is rapidly progressing aimed to solve several limitations of conventional drug delivery systems. Nonspecific target of cancer chemotherapy leads to damage rapidly proliferating normal cells and can be significantly reduced through folate and transferrin mediated nanotherapeutics which are aimed to target cancerous cells. Multidrug resistance is challenge in cancer chemotherapy which can be significantly reversed by solid lipid nanoparticles, polymeric nanoparticles, mesoporous silica nanoparticles, nanoparticulated chemosensitizer, nanoparticluated poloxamer and magnetic nanoparticles. Hydrophobic nature of chemotherapeutics leads to poor aqueous solubility and low bioavailability which can be overcome by nanocrystals, albumin based nanoparticles, liposomal formulation, polymeric micelles, cyclodextrin and chitosan based nanoparticles. This review focuses the role of nanotherapeutics to overcome lack of selectivity, multidrug resistance and lack of aqueous solubility of conventional cancer chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Triblock Copolymer Syntheses of Mesoporous Silica with Periodic 50 to 300 Angstrom Pores
Zhao, D., Feng, J., Huo, Q., Melosh, N., Fredrickson, G. H., Chmelka, B. F., & Stucky, G. D. (1998) · Science · doi:10.1126/science.279.5350.548 · Cited by 11,753
A new family of mesoporous molecular sieves prepared with liquid crystal templates
Beck, J. S., Vartuli, J. C., Roth, W. J., Leonowicz, M. E., Kresge, C. T., Schmitt, K. D., Chu, C. T. W., Olson, D. H., Sheppard, E. W., McCullen, S. B., et al. (1992) · Journal of the American Chemical Society · doi:10.1021/ja00053a020 · Cited by 10,967
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Drug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
Therapeutic Nanoparticles for Drug Delivery in Cancer
Cho, K., Wang, X., Nie, S., Chen, Z. (., & Shin, D. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1441 · Cited by 2,920
Nanoparticle and targeted systems for cancer therapy
Brannon-Peppas, L., & Blanchette, J. O. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.02.014 · Cited by 2,334
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151
(2016) · CRC Press eBooks · doi:10.1201/b12801 · Cited by 2,031
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Yanagisawa, T., Shimizu, T., Kuroda, K., & Kato, C. (1990) · Bulletin of the Chemical Society of Japan · doi:10.1246/bcsj.63.988 · Cited by 1,783
Cyclodextrins and their pharmaceutical applications
LOFTSSON, T., & DUCHENE, D. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.10.044 · Cited by 1,764
The Human ATP-Binding Cassette (ABC) Transporter Superfamily
Dean, M., Rzhetsky, A., & Allikmets, R. (2001) · Genome Research · doi:10.1101/gr.184901 · Cited by 1,748
Openings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689
The human ATP-binding cassette (ABC) transporter superfamily
Dean, M., Hamon, Y., & Chimini, G. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31588-1 · Cited by 1,302
Mohanraj, V. J., & Chen, Y. (2007) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v5i1.14634 · Cited by 1,217
Desai, N., Trieu, V., Yao, Z., Louie, L., Ci, S., Yang, A., Tao, C., De, T., Beals, B., Dykes, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1634 · Cited by 1,175
Trewyn, B. G., Slowing, I. I., Giri, S., Chen, H.-T., & Lin, V. S.-Y. (2007) · Accounts of Chemical Research · doi:10.1021/ar600032u · Cited by 1,123
The Human ATP-Binding Cassette (ABC) Transporter Superfamily
Dean, M. (2001) · Genome Research · doi:10.1101/gr.gr-1649r · Cited by 1,113
Nanocrystal technology, drug delivery and clinical applications
Müller, R., & Junghanns (2008) · International Journal of Nanomedicine · doi:10.2147/ijn.s595 · Cited by 953
Transport of molecules across tumor vasculature
Jain, R. K. (1987) · CANCER AND METASTASIS REVIEW · doi:10.1007/bf00047468 · Cited by 866
Rang, H. P., & Dale, M. M. (2012) · Andalas University Repository (Andalas University) · Cited by 829
Microencapsulation : methods and industrial applications
Benita, S. (1996) · Medical Entomology and Zoology · Cited by 806
Protein nanoparticles as drug carriers in clinical medicine
Hawkins, M. J., Soon-Shiong, P., & Desai, N. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.044 · Cited by 779
Poly(ethylene oxide)-block-poly(l-amino acid) micelles for drug delivery
Lavasanifar, A., Samuel, J., & Kwon, G. S. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00015-7 · Cited by 756
The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis
Gelperina, S., Kisich, K., Iseman, M. D., & Heifets, L. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200504-613pp · Cited by 745
Application of Nanotechnology in Cancer Therapy and Imaging
Wang, X., Yang, L., Chen, Z., & Shin, D. M. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0003 · Cited by 700
Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
Tomao, S. (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s3061 · Cited by 695 · cited 1×
“physically enhances the stability and half-life of the drug (76-83).”
BackgroundDvorak, H. F., Nagy, J. A., Dvorák, J., & Dvořàk, A. M. (1988) · PubMed Central · Cited by 679
Chen, A. M., Zhang, M., Wei, D., Stueber, D., Taratula, O., Minko, T., & He, H. (2009) · Small · doi:10.1002/smll.200900621 · Cited by 671
Poly(ethylene glycol)-modified Nanocarriers for Tumor-targeted and Intracellular Delivery
van Vlerken, L. E., Vyas, T. K., & Amiji, M. M. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9284-6 · Cited by 645
Pharmacological Effects of Formulation Vehicles: Implications for Cancer Chemotherapy
ten Tije, A. J., Verweij, J., Loos, W. J., & Sparreboom, A. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342070-00005 · Cited by 591
Üner, M., & Yener, G. (2007) · PubMed Central · Cited by 543
The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells
Daniels, T. R., Delgado, T., Helguera, G., & Penichet, M. L. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.06.006 · Cited by 518
Polymeric Micelles for Delivery of Poorly Water-Soluble Compounds
Kwon, G. S. (2003) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v20.i5.20 · Cited by 502 · cited 1×
“or synthetic are hydrophobic and requires solvents to formulate the dosage form which contribute to severe toxicity, (b) Lack of selectivity of anticancer drugs: Most chemotherapeutics lack selectivity toward cancerous cells cause significant damage to rapidly proliferating normal cells and (c) Multidrug resistance (M…”
BackgroundOverexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
Maliepaard, M., van Gastelen, M. A., de Jong, L. A., Pluim, D., van Waardenburg, R. C., Ruevekamp, M. C., Floot, B. G., & Schellens, J. H. M. (1999) · PubMed · Cited by 487
Extracellularly Activated Nanocarriers: A New Paradigm of Tumor Targeted Drug Delivery
Gullotti, E., & Yeo, Y. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900090z · Cited by 473
Chitosan nanoparticles for oral drug and gene delivery
Bowman, K., & Leong, K. W. (2006) · International Journal of Nanomedicine · doi:10.2147/nano.2006.1.2.117 · Cited by 439
Poly(l-glutamic acid)–anticancer drug conjugates
Li, C. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00045-5 · Cited by 414
Nanosystems in Drug Targeting: Opportunities and Challenges
Vasir, J. K., Reddy, M. K., & Labhasetwar, V. D. (2005) · Current Nanoscience · doi:10.2174/1573413052953110 · Cited by 414
Heath, J. R., & Davis, M. E. (2008) · Annual Review of Medicine · doi:10.1146/annurev.med.59.061506.185523 · Cited by 354
Cellular mechanisms of multidrug resistance of tumor cells.
Stavrovskaya, A. A. (2000) · PubMed · Cited by 344
Zhang, J. A., Anyarambhatla, G., Ma, L., Ugwu, S., Xuan, T., Sardone, T., & Ahmad, I. (2005) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.06.009 · Cited by 334
Jain, R. K. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00306-6 · Cited by 298
Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood–brain barrier
Chang, J., Jallouli, Y., Kroubi, M., Yuan, X.-B., Feng, W., Kang, C.-S., Pu, P.-Y., & Betbeder, D. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.04.035 · Cited by 278
Mulik, R. S., Mönkkönen, J., Juvonen, R. O., Mahadik, K. R., & Paradkar, A. R. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.07.021 · Cited by 260
Nanotechnology: What it can do for drug delivery
Park, K. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.05.003 · Cited by 239
Elwood, P. C. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)63786-x · Cited by 233
Advances of Cancer Therapy by Nanotechnology
Wang, X., Wang, Y., Chen, Z. G., & Shin, D. M. (2009) · Cancer Research and Treatment · doi:10.4143/crt.2009.41.1.1 · Cited by 230
Folic Acid-Mediated Targeting of Cowpea Mosaic Virus Particles to Tumor Cells
Destito, G., Yeh, R., Rae, C. S., Finn, M. G., & Manchester, M. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.08.015 · Cited by 225
Colloidal stability of Pluronic F68-coated PLGA nanoparticles: A variety of stabilisation mechanisms
Santander-Ortega, M. J., Jódar-Reyes, A. B., Csaba, N., Bastos-González, D., & Ortega-Vinuesa, J. L. (2006) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2006.07.031 · Cited by 221
Song, X. R., Cai, Z., Zheng, Y., He, G., Cui, F. Y., Gong, D. Q., Hou, S. X., Xiong, S. J., Lei, X. J., & Wei, Y. Q. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.02.018 · Cited by 211
Zhang, Z., Jia, J., Lai, Y., Ma, Y., Weng, J., & Sun, L. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.06.045 · Cited by 199
Interstitial fluid pressure in breast cancer, benign breast conditions, and breast parenchyma
Nathanson, S. D., & Nelson, L. (1994) · Annals of Surgical Oncology · doi:10.1007/bf03187139 · Cited by 197
High affinity binding of paclitaxel to human serum albumin
Paál, K., Müller, J., & Hegedûs, L. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.02107.x · Cited by 191
Interaction of taxol with human serum albumin
Purcell, M., Neault, J. F., & Tajmir-Riahi, H. A. (2000) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(99)00251-4 · Cited by 189
Paclitaxel Nanocrystals for Overcoming Multidrug Resistance in Cancer
Liu, Y., Huang, L., & Liu, F. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100012s · Cited by 168
Targeted Cancer Therapy With Novel High Drug-Loading Nanocrystals
Liu, F., Park, J.-Y., Zhang, Y., Conwell, C., Liu, Y., Bathula, S. R., & Huang, L. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22112 · Cited by 159
Agüeros, M., Zabaleta, V., Espuelas, S., Campanero, M. A., & Irache, J. M. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.03.012 · Cited by 156
Zhao, X. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.01.005 · Cited by 153
Cancer-Targeted Polymeric Drugs
Luo, Y., & Prestwich, G. (2002) · Current Cancer Drug Targets · doi:10.2174/1568009023333836 · Cited by 147
Alakhova, D. Y., Rapoport, N. Y., Batrakova, E. V., Timoshin, A. A., Li, S., Nicholls, D. G., Alakhov, V. Y., & Kabanov, A. V. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.09.026 · Cited by 145
Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy
Kang, K. W., Chun, M., Kim, O., Subedi, R. K., Ahn, S., Yoon, J., & Choi, H. (2010) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2009.12.006 · Cited by 142
The Human ATP-Binding Cassette Transporter Genes From the Bench to the Bedside
Efferth, T. (2001) · Current Molecular Medicine · doi:10.2174/1566524013364194 · Cited by 139
Zhang, Y., Tang, L., Sun, L., Bao, J., Song, C. X., Huang, L., Liu, K., Tian, Y., Tian, G., Li, Z., et al. (2009) · Acta Biomaterialia · doi:10.1016/j.actbio.2009.11.035 · Cited by 134
Zheng, Y., Yu, B., Weecharangsan, W., Piao, L., Darby, M. V., Mao, Y., Koynova, R. D., Yang, X., Li, H., Xu, S., et al. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.02.008 · Cited by 133
Aberrant vascular architecture in tumors and its importance in drug-based therapies
Munn, L. L. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02686-2 · Cited by 123
Synthesis and evaluation of a novel ligand for folate-mediated targeting liposomes
Xiang, G., Wu, J. H., Lu, Y., Liu, Z., & Lee, R. J. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.12.030 · Cited by 121
Zhang, C., Zhao, L., Dong, Y., Zhang, X., Lin, J., & Chen, Z. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.05.005 · Cited by 120
Preparation, characterization and properties in vitro and in vivo of a paclitaxel–albumin conjugate
Dosio, F., Brusa, P., Crosasso, P., Arpicco, S., & Cattel, L. (1997) · Journal of Controlled Release · doi:10.1016/s0168-3659(97)01656-8 · Cited by 116
Zhang, C., Ding, Y., Yu, Q., & Ping, Q. (2006) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2006.11.031 · Cited by 109
Henderson, I. C., & Bhatia, V. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.7.919 · Cited by 102
Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant
Sharma, A. K., Zhang, L., Li, S., Kelly, D. L., Alakhov, V. Y., Batrakova, E. V., & Kabanov, A. V. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.07.031 · Cited by 92
Expression of iron-related genes in human brain and brain tumors
Hänninen, M., Haapasalo, J. A., Haapasalo, H. K., Fleming, R. E., Britton, R. S., Bacon, B. R., & Parkkila, S. (2009) · BMC Neuroscience · doi:10.1186/1471-2202-10-36 · Cited by 92
Li, X., Yang, Z., Yang, K., Zhou, Y., Chen, X., Zhang, Y., Wang, F., Liu, Y., & Ren, L. (2009) · Nanoscale Research Letters · doi:10.1007/s11671-009-9427-2 · Cited by 91
Drug Targeting in Cancer Chemotherapy: A Clinical Perspective
Gupta, P. K. (1990) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600791102 · Cited by 84
Relevance of folic acid/polymer ratio in targeted PEG–epirubicin conjugates
Canal, F., Vicent, M. J., Pasut, G., & Schiavon, O. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.05.027 · Cited by 82
Role of organelle pH in tumor cell biology and drug resistance
Simon, S. M. (1999) · Drug Discovery Today · doi:10.1016/s1359-6446(98)01276-8 · Cited by 60
Liu, Y., Chen, G., Chen, Y., Dong-xu, C., Ge, Z.-Q., & Yuan, Y. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.08.040 · Cited by 54
Foote, M. (2007) · Biotechnology annual review · doi:10.1016/s1387-2656(07)13012-x · Cited by 53
Nanocrystals of Poorly Soluble Drugs for Oral Administration
Bushrab, F. N., & Müller, R. H. (2003) · Cited by 43
Chen, B. (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s7287 · Cited by 36
Lam, K. H., Leung, C., Chan, H., & Fong, W. F. (2000) · Anti-Cancer Drugs · doi:10.1097/00001813-200006000-00008 · Cited by 33
Trewyn, B. G., Slowing, I. I., Giri, S., Chen, H., & Lin, V. S. ‐. (2007) · ChemInform · doi:10.1002/chin.200750256 · Cited by 25
Cited by
Nanomaterials for Theranostics: Recent Advances and Future Challenges
Lim, E.-K., Kim, T., Paik, S., Haam, S., Huh, Y.-M., & Lee, K. (2015) · Chemical Reviews · doi:10.1021/cr300213b · Cited by 1,233
Therapeutic Nanoparticles and Their Targeted Delivery Applications
Yetisgin, A. A., Cetinel, S., Zuvin, M., Kosar, A., & Kutlu, O. (2020) · Molecules · doi:10.3390/molecules25092193 · Cited by 1,080
Kalyane, D., Raval, N., Maheshwari, R., Tambe, V., Kalia, K., & Tekade, R. K. (2019) · Materials Science and Engineering: C · doi:10.1016/j.msec.2019.01.066 · Cited by 849
PLGA-Based Nanoparticles in Cancer Treatment
Rezvantalab, S., Drude, N. I., Moraveji, M. K., Güvener, N., Koons, E. K., Shi, Y., Lammers, T., & Kiessling, F. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01260 · Cited by 607
Delivery of therapeutic agents by nanoparticles made of grapefruit-derived lipids
Wang, Q., Zhuang, X., Mu, J., Deng, Z.-B., Jiang, H., Zhang, L., Xiang, X., Wang, B., Yan, J., Miller, D., et al. (2013) · Nature Communications · doi:10.1038/ncomms2886 · Cited by 525
Metadata
- Authors
- Chidambaram, M., Manavalan, R., & Kathiresan, K.
- Venue
- Journal of Pharmacy & Pharmaceutical Sciences
- Publisher
- Frontiers Media SA
- Published
- 2011-02-16
- Volume
- 14
- Issue
- 1
- Pages
- 67
- ISSN
- 1482-1826 (ISSN-L)
- OpenAlex
- W1571365882
- Cited by
- 566
- References
- 85
- FWCI
- 7.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.